Novo’s latest alliance involves injectables given every one to three months. Elsewhere, Nektar won a legal spat with Eli Lilly and the FDA issued two approvals.

Original title: “Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data”

Panel members said the first-of-a-kind blood test should not be used to replace medical guideline-recommended cancer screenings, however.

Original title: “Grail multicancer detection test wins FDA advisers’ backing”

Basecamp Research joins the growing group of AI-forward biotechs that in recent months have brought in notable sums from investors, including Isomorphic Labs and Enveda.

Original title: “Backed by NVIDIA and Anthropic, Basecamp bags $140M to advance AI-designed drugs”

Basecamp Research joins the growing group of AI-forward biotechs that in recent months have brought in notable sums from investors, including Isomorphic Labs and Enveda.

Original title: “Backed by NVIDIA, Basecamp bags $140M to advance AI-designed drugs”

The new partnership follows Roche’s recent R&D expansion in Boston focused on development for cardiovascular, renal and metabolic diseases.

Original title: “Roche inks up to $2B deal with Atavistik for new cardiometabolic drugs”

The ACF, ORR, Refugee Program Bureau announces the intent to solicit and award a single-source cooperative agreement up to $20,000,000 to International Rescue Committee (IRC), in New York, New York, for the National Virtual Program for Professional Advancement. The proposed project period is September 30, 2026, through September 29, 2027. Under this initiative, IRC will use its nationwide virtual service delivery model to provide professional advancement services to up to 1,334 eligible refugees

Original title: “Announcement of the Intent To Award a Single-Source Cooperative Agreement to International Rescue Committee in New York, New York”